Loading...
Market
What will be the main challenge for US plutonium pit production by end of 2025?
2
Resolution / Starting Odds
Legal challenges • 25%
Technical difficulties • 25%
Funding issues • 25%
Other challenges • 25%
Reports from the US Department of Energy or investigative journalism by major news outlets.
Story
US Energy Department Produces First Plutonium Pit Since 1989 Amid Mass Production and Supreme Court Review
Oct 11, 2024, 08:02 PM
The United States Department of Energy has manufactured its first plutonium pit since 1989, marking a significant step in nuclear weapons production. This plutonium pit is crucial for the core of thermonuclear warheads, which initiate explosions. While the Energy Department is reportedly moving towards mass production of these warhead-ready pits, uncertainties remain, particularly following a recent federal court ruling that may impact the future of such production. Additionally, the Supreme Court is set to review the legality of temporary storage facilities for nuclear waste, a decision that could significantly influence the nation’s nuclear energy strategy.
View original story
Similar markets
Technical Challenges • 25%
Regulatory Hurdles • 25%
Funding Issues • 25%
Supply Chain Constraints • 25%
Regulatory hurdles • 25%
Technical issues • 25%
Financial constraints • 25%
Public opposition • 25%
Administrative delays • 25%
Language barriers • 25%
Cultural integration issues • 25%
Legal/visa issues • 25%
Yes • 50%
No • 50%
Yield improvement • 25%
Cost reduction • 25%
Integration with vehicles • 25%
Other manufacturing issue • 25%
Technical challenges • 25%
Financial constraints • 25%
Regulatory hurdles • 25%
Public opposition • 25%
Engineering issues • 25%
Regulatory delays • 25%
Financial constraints • 25%
Environmental concerns • 25%
Russia • 25%
China • 25%
North Korea • 25%
Iran • 25%
Increase in warhead count • 25%
Development of new delivery systems • 25%
Modernization of existing arsenal • 25%
Other • 25%
Radiation levels • 25%
Technical limitations • 25%
Logistical issues • 25%
Regulatory hurdles • 25%
Immune rejection • 25%
Infection risk • 25%
Ethical concerns • 25%
Supply chain issues • 25%
Scalability • 25%
Error correction • 25%
Cost reduction • 25%
Integration with classical systems • 25%